Course Information

Introduction to Safe Prescribing: Opioids, Benzodiazepines, and Stimulants

Introduction to Safe Prescribing: Opioids, Benzodiazepines, and Stimulants

Canada is in the midst of an opioid crisis and this crisis has been recognized at all levels of government and has been the subject of several recent editorials in the Canadian medical press. There are calls to improve awareness among prescribers about the crisis and to improve their knowledge of prescribing opioids. By extension, it is also important to consider the prescribing of stimulant and sedative – hypnotic medications (benzodiazepine) medications. These medications are also potentially addictive and have serious side effects and complications associated with them. Additionally, prescribing of benzodiazepines and opioids in combination may place the patient at significant risk.

It is therefore crucial that we begin learning the basics of prescribing these medications early in our career. Knowledge of safe and effective prescribing is important in all specialties to keep our patients and ourselves safe.

After completing this course, you will be able to: 

  1. Recognize the indications for and goals of prescribing opioids, benzodiazepines and stimulants.
  2. Define how to set boundaries to ensure safe prescribing of opioids, benzodiazepines and stimulants.
  3. Identify the prescriber and patient risks inherent in prescribing opioids, benzodiazepines and stimulants.
  4. Outline the key features of an opioid, benzodiazepine or stimulant trial
  5. List the aberrant behaviours that may be associated with prescribing opioids, benzodiazepines and stimulants.

This continuing professional development (CPD) program has been designed to consider the following roles as defined by the CanMEDS Physician Competency Framework:

  • Family Medicine/Medical Expert
  • Communicator
  • Collaborator


Registration Fee

The cost to register for this module is $150.00 CDN.

Once you click the Register button, you will be taken to Moneris - Canada's leading processor of debit and credit card payments - to process your registration fee. Upon payment of the registration fee, you will be returned to this site and will have immediate access to your learning module.


Course Registration

Introduction to Safe Prescribing: Opioids, Benzodiazepines, and Stimulants

MDcme (on behalf of its consortium partners) protects the privacy of personal and other information regarding course registrants. MDcme will not release personally identifiable information to a third party without an individual's consent, except such information as is required for reporting purposes to the body or bodies accrediting this course for continuing education study credits. MDcme collects and reviews all course data (registration/course completion statistics, pre/post-test and satisfaction survey) to determine if a course meets participants' learning needs. Data is reviewed to improve existing courses and to inform the development of future course offerings. If an evaluation report is provided to a third party, all data is summarized, with no participant identifying information included. Given the importance and potential impact of some courses, evaluation data may be presented and/or published in academic venues. Again, this data is always summarized, with no identifying information included.

At times, a contributing/partner organization involved in a course may request individual participant data from pre/post or evaluation surveys for quality improvement or educational research purposes. This data would be de-identified so would not be associated with any personally identifiable information such as your name, profession, city, etc.

If requested by a contributing/partner organization:

Do you consent to the release of your individual, de-identified pre/post or evaluation survey data for the purposes of quality improvement or educational research?


×

You must have an MDcme.ca account and be logged in to register for this course


Credits


Accreditation

Accreditation for this course expires on
Wednesday, August 3, 2022